Precision Medicine for Older AML Patients

Onco · Published 2025-09-16 · DOI 10.3390/onco5030042

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.3390/onco5030042

Abstract

The development of molecular profiling approaches for AML patients such as whole genome sequencing, whole exome sequencing and transcriptomic sequencing have greatly contributed to better understanding of leukemia development, progression and treatment responsiveness/resistance. These studies have generated a new knowledge about driver events operating in AML that can be translated into clinics, thus favoring the mutations; using this approach, more than 50% of older AML patients display molecular alterations, such as <i>IDH1</i>, <i>IDH2</i>, <i>FLT3</i> (<i>FLT3-TKD</i> and <i>FLT3-ITD</i>), <i>NPM1</i> and <i>KMT2A</i> rearrangements that can be targeted by specific drugs. Preclinical and clinical studies have supported the use of drugs targeting these molecular alterations as first-line therapy in association with induction chemotherapy in chemotherapy-fit patients or with a hypomethylating agent in association with a Bcl-2 inhibitor (Venetoclax) in chemotherapy-unfit patients. These studies have shown promising results that need to be confirmed through randomized clinical studies specifically involving the enrollment of older AML patients.

Abstract from DOAJ. Public domain (CC0 1.0).

Read the article at the publisher →

Publication details

Year
2025

Related articles